

## เอกสารอ้างอิง: ลูทีน และ แซนทีน

1. Roberts RL, Green J, Lewis B. Lutein and zeaxanthin in eye and skin health. *Clinics in Dermatol* 2009; 27: 195-201.
2. Johnson EJ. The role of carotenoids in human health. *Nutr Clin Care* 2002; 5: 56-65.
3. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. *Annu Rev Nutr* 2003; 23: 171-201.
4. Ojima F, Sakamoto H, Ishiguro Y, Terao J. Consumption of carotenoids in photosensitized oxidation of human plasma and plasma low-density lipoprotein. *Free Radical Biol Med* 1993; 15: 337-84.
5. Able Jr. R. The eye care resolution: prevent and reverse vision problems. New York: Kensington Books; 1999, p. 41-6.
6. Ham Jr. W, Mueller H, Sliney D. Retinal sensitivity to damage from short wavelength of light. *Nature* 1976; 260: 153-5.
7. Beatty S, Boulton M, Henson D, Koh H, Murray I. Macular pigment and age-related macular degeneration. *Br J Ophthalmol* 1999; 83: 867-77.
8. Beatty S, Nolan J, Kavanagh H, O'Donovan. Macular pigment optical density and its relationships with serum and dietary levels of lutein and zeaxanthin. *Arch Biochem Biophys* 2004; 430: 70-6.
9. Koh H, Murray I, Nolan D, Carden D, Feather J, Beatty S. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. *Exp Eye Res* 2004; 79: 21-7.
10. Sujak A, Gabrielska J, Grudzinski W, Borc R, Mazurek P, Gruszecki W. Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects. *Arch Biochem Biophys* 1999; 371: 301-7.
11. Ruffolo Jr J, Ham Jr T, Mueller H, Millen J. Photochemical lesions in the primate retina under controlled conditions of elevated blood oxygen. *Invest Ophthalmol Vis Sci* 1984; 25: 893-8.
12. Handelman G, Dratz E, Reay C, van Kuijk J. Carotenoids in the human macula and whole retina. *Invest Ophthalmol Vis Sci* 1988; 29: 850-8.
13. Bone R, Landrum J, Tarsis S. Preliminary identification of the human macular pigment. *Vis Res* 1985; 25: 1531-5.
14. Snodderly D, Handelman G, Adler A. Distribution of individual macular pigment carotenoids in central retina of macaque and squirrel monkeys. *Invest Ophthalmol Vis Sci* 1991; 32: 268-79.
15. Bone R, Landrum J. Distribution of macular pigment components, zeaxanthin and lutein, in human retina. *Methods Enzymol* 1991; 213: 360-6.
16. Landrum J, Bone R. Lutein, zeaxanthin, and the macular pigment. *Arch Biochem Biophys* 2001; 385: 28-40.
17. Bone R, Landrum J, Friedes L, et al. Distribution of lutein and zeaxanthin stereoisomers in the human retina. *Exp Eye Res* 1997; 64: 211-8.
18. Chung HY, Rasmussen H, Johnson EJ. Lutein bioavailability is higher from lutein-enriched eggs than from supplements and spinach in men. *J Nutr* 2004; 134: 1857-93.
19. Brown I, Rimm EB, Seddon JM, et al. A prospective study of carotenoid intake and risk of cataract extraction in US men. *Am J Clin Nutr* 1999; 70: 517-24.
20. Chasan-Taber I, Willett WC, Seddon JM, Stamper MJ, Rosner B, Colditz GA. A prospective study on vitamin supplement intake and cataract extraction among US women. *Epidemiology* 1999; 10: 679-84.

21. Chasan-Taber L, Willett WC, Seddon JM, et al. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. *Am J Clin Nutr* 1999; 70: 509-16.
22. Seddon J, Anani A, Sperduto R, et al. Dietary carotenoids, vitamin A, C, E and advanced age-related macular degeneration. Eye Disease Case Controlled Study Group. *JAMA* 1994; 272: 1413-20.
23. Evans JA, Johnson EJ. Something new under the sun: lutein's role in skin health. *AJLM* 2009;3(5):349-52.
24. Klaver C, Wolfs R, Vingerling J, Hofman J, de Jong P. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. *Arch Ophthalmol* 1998; 116: 653-8.
25. Johnson E. Obesity, lutein metabolism, and age-related macular degeneration: a web of connections. *Nutr Rev* 2005; 63: 9-15.
26. Klein R, Zeiss C, Chew E, et al. Complement factor H polymorphism in age-related macular degeneration. *Science* 2005; 308: 385-9.
27. Christen W. Antioxidant vitamins and age-related eye diseases. *Proc Assoc Am Physicians* 1999; 111: 16-21.
28. Cai J, Nelson K, Wu M, Sternberg P, Jones D. Oxidative damage and protection of RPE. *Prog Retin Eye Res* 2000; 19: 205-21.
29. <http://www.kellogg.umich.edu/patientcare/conditions/amd.h>
30. [http://www.nei.nih.gov/health/maculardegen/armd\\_facts.asp](http://www.nei.nih.gov/health/maculardegen/armd_facts.asp)
31. Ma Le, Lin XM. Effects of lutein and zeaxanthin on aspects of eye health. *J Sci Food Agri* 2010; 90: 2-12.
32. Snellen ELM, Verbeek ALM, van den Hoogen GWP, Cruysberg JRM, Hoyng CB. Neovascular age-related macular degeneration and its relationship to antioxidant intake. *Acta Ophthalmol Scand* 2002; 80: 368371.
33. Moeller S, Parekh N, Tinker L, et al. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. *Arch Ophthalmol* 2006; 124: 1151-62.
34. AREDS Research Group. The relationship of dietary carotenoids and vitamin A, E, and C intake with age-related macular degeneration in a case-control study. AREDS Report no. 22. *Arch Ophthalmol* 2007; 125: 1225-32.
35. Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. *Ophthalmology* 2008; 115: 334-41.
36. Robman L, Vu H, Hodge A, et al. Dietary lutein, zeaxanthin, and fats and the progression of age-related macular degeneration. *Can J Ophthalmol* 2007; 42: 720-6.
37. Cho E, Hankinson SE, Rosner B, Willett WC, Colditz GA. Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. *Am J Clin Nutr* 2008; 1837-43.
38. Eye Disease Case-Control Study Group. Antioxidant status and neovascular age-related macular degeneration. *Arch Ophthalmol* 1993; 111: 104-9.
39. Gale CR, Hall NF, Phillips DIW, Martyn CN. Lutein and zeaxanthin status and risk of age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2003; 44: 2461-5.
40. Delcourt C, Carriere I, Delage M, Barberger-Gateau P, Schalch W. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: The POLA Study. *Invest Ophthalmol Vis Sci* 2006; 47: 2329-35.
41. Mares-Perlman JA, Brady WE, Klein R, et al. Serum antioxidants and age-related macular degeneration in a population-based case-control study. *Arch Ophthalmol* 1995; 113: 1518-23.

42. Landrum JT, Bone RA, Joa H, Killburn MD, Moore LL, Sprague KE. A one year study of the macular pigment: the effect of 140 days of a lutein supplement. *Exp Eye Res* 1997; 65: 57-62.
43. Rosenthal JM, Kim J, de Monaterio F, et al. Dose-ranging study of lutein supplementation in persons aged 60 years or older. *Invest Ophthalmol Vis Sci* 2006; 47: 5227-33.
44. Huang LL, Coleman HR, Kim J, et al. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. *Invest Ophthalmol Vis Sci* 2008; 49: 3864-9.
45. Trieschmann M, Beatty S, Nolan JM, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. *Exp Eye Res* 2007; 84: 718-28.
46. Weigert G, Kaya S, Pemp B, Sacu S, Lasta M, Werkmeister RM, Dragostinoff N, Simader C, Garhofer G, Schmidt-Erfurth U, et al. Effect of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2011; 52: 8174-8.
47. Ma L, Yan SF, Huang YM, et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. *Ophthalmology* 2012a; 119: 2290-7.
48. Ma L, Dou HL, Huang YM, et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: A randomized, double-masked, placebo-controlled trial. *Am J Ophthalmol* 2012b; 154: 625-34.
49. Cangemi FE. TOZAL Study: an open case-control study of an oral antioxidant and omega-3 supplement for dry AMD. *BMC Ophthalmol* 2007; 7: 3.
50. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). *Optometry* 2004; 75: 216-30.
51. Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S. Carotenoids and antioxidants in age-related maculopathy Italian study: multifocal electroretinogram modifications after 1 year. *Ophthalmology* 2008; 115: 324-33.
52. Lin D, Barnett M, Grauer L, Robben J, Jewell A, Takemoto L, et al. Expression of superoxide dismutase in whole lens prevents cataract formation. *Mol Vis* 2005; 11: 853-8.
53. [https://www.nei.nih.gov/health/cataract/cataract\\_facts.asp](https://www.nei.nih.gov/health/cataract/cataract_facts.asp)
54. Wong TY, Klein BE, Klein R, Tomany SC, Lee KE. Refractive errors and incident cataracts: the Beaver Dam Eye Study. *Invest Ophthalmol Vis Sci* 2001; 42: 1449-54.
55. Chiu CJ, Morris MS, Rogers G, Jacques PF, Chylack LTJ, Tung W, et al. Carbohydrate intake and glycemic index in relation to the odds of early cortical and nuclear lens opacities. *Am J Clin Nutr* 2005; 81: 1411-6.
56. Lyle BJ, Mares-Perlman JA, Klein BE, Klein R, Greger JL. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. *Am J Epidemiol* 1999; 149: 801-9.
57. Vu HT, Robman L, Hodge A, McCarty CA, Taylor HR. Lutein and zeaxanthin and the risk of cataract.: The Melbourne Visual Impairment Project. *Invest Ophthalmol Vis Sci* 2006; 47: 3783-6.
58. Moeller SM, Voland R, Tinker L, Blodi BA, Klein ML, Gehrs KM, et al. Associations between age-related nuclear cataract and lutein and zeaxanthin in the diet and serum in the Carotenoids in the Age-related Eye Disease Study, an Ancillary Study of the Women's Health Initiative. *Arch Ophthalmol* 2008; 126: 354-64.

59. Christen WG, Liu S, Glynn RJ, Gaziano JM, Buring JE. Dietary carotenoids, vitamins C and E, and risk of cataract in women: a prospective study. *Arch Ophthalmol* 2008; 126: 1606-7.
60. Gale CR, Hall NF, Phillips DIW, Martyn CN. Plasma antioxidant vitamins and carotenoids and age-related cataract. *Ophthalmology* 2001; 108: 1992-8.
61. Olmedilla B, Granado F, Blanco I, Vaquero M, Cajigal C. Lutein in patients with cataracts and age-related macular degeneration: a longterm supplementation study. *J Sci Food Agric* 2001; 81: 904-9.
62. Olmedilla B, Granado F, Blaco I, Vaquero M. Lutein, but not alphatocopherol, supplementation improves visual function in patients with age-related cataracts: a 2 year double-blind, placebo-controlled pilot study. *Nutrition* 2003; 19:21-4.
63. [http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH\\_0002024](http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH_0002024)
64. Heckenlively JR, Yoser SL, Friedman LH, Oversier JJ. Clinical findings and common symptoms in retinitis pigmentosa. *Am J Ophthalmol* 1988; 105: 504-11.
65. Dagnelie G, Zorge IS, McDonald TM. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. *Optometry* 2000; 71: 147-64.
66. Aleman TS, Duncan JL, Bieber ML, de Castro E, Marks DA, Gardner LM, et al. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. *Invest Ophtahlmol Vis Sci* 2001; 42: 1873-881.
67. Bahrami H, Melia M, Dagnelie G. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized couple-masked placebo-controlled clinical data. *BMC Ophtahlmol* 2006; 6: 23.
68. Adackapara CA, Sunness JS, Dibernardo CW, Melia BM, Dagnelie G. Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. *Retina* 2008; 28: 103-10.
69. <http://www.nei.nih.gov/health/diabetic/retinopathy.asp>
70. Koushan K, Rusovici R, Wenhua L, Ferguson LR, Chalam KV. The role of lutein in eye-related disease. *Nutrients* 2013; 5: 1823-39.
71. Hu BJ, Hu YN, Lin S, Ma WJ, Li XR. Application of lutein and zeaxanthin in nonproliferative diabetic retinopathy. *Int J Ophtahlmol* 2011; 4: 303-6.
72. <http://www.nei.nih.gov/health/retinaldetach/retinaldetach.asp>
73. Chan C, Leung I, Lam KW, Tso MO. The occurrence of retinol and carotenoids in human subretinal fluid. *Curr Eye Res* 1998; 17: 890-5.